How Many Clicks Does a 7.5mg Mounjaro Pen Deliver?

What the licensed prescribing schedule says about 7.5mg

The Mounjaro SmPC (the official product information held on the Electronic Medicines Compendium) sets out six available strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. Treatment begins at 2.5mg, with each step up typically separated by at least four weeks, depending on tolerability and clinical progress. The 7.5mg step sits in the middle of that ladder, usually reached after at least eight weeks on treatment. It's prescribed because the titration schedule is designed to give the body time to adjust before the dose is raised again, not as a permanent ceiling for most patients.

A question our prescribers hear most weeks is whether the pen itself tells you when to move to the next dose. It doesn't. The pen delivers whatever strength it contains; the timing of any dose change is a clinical decision made by your prescriber, not something the pen signals or automates. If you're on 7.5mg and wondering whether 10mg might be next, that conversation belongs in a clinical review. Our page on the 10mg Mounjaro pen covers how that strength works mechanically, should your prescriber move you up.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that participants who reached the 15mg maintenance dose achieved around 20–21% average body-weight reduction over 72 weeks. Those findings frame why the titration schedule matters: tolerability at each step shapes whether patients can reach and sustain the doses where the greatest effect was observed.

The KwikPen mechanism at 7.5mg, one press, not multiple clicks

The Mounjaro KwikPen is engineered to remove guesswork from injection technique. Unlike some devices where a patient counts clicks to measure a dose, the KwikPen is pre-filled and pre-set. At 7.5mg, the dose is fixed inside the pen. You do not dial it. You do not count multiple clicks to reach it.

What you do hear is a click when the injection begins and a second click when it is complete, some patients describe a faint second sound partway through the hold, then the end signal. The Patient Information Leaflet that comes with your pen describes this two-stage feedback precisely, and that document is the authority. Reading it before your first injection of a new strength is genuinely useful, not just a formality.

If you started treatment at 2.5mg, the mechanics of the pen at that strength are described separately, the 2.5mg dose on a 7.5mg pen page covers the specific nuance of starter doses delivered via a higher-labelled pen, which can look confusing on the packaging. Each 7.5mg pen holds four doses; there is no partial-pen situation at this strength under normal prescribing.

Injection sites are the abdomen, the thigh, or the upper arm. Rotating the site for each dose reduces the chance of local skin reactions. Storage is refrigerated at 2–8°C; once removed from the fridge, the pen can be kept at room temperature for a limited period, the Patient Information Leaflet gives the exact window, and that window varies by storage conditions, so don't rely on a round number from an article.

Why 7.5mg sits where it does in a clinical treatment plan

The titration schedule isn't arbitrary. Mounjaro activates both GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite. At lower doses, the body is adapting to that mechanism; nausea, in particular, tends to be more pronounced in early weeks and then settles. The step from 5mg to 7.5mg typically happens after the 5mg dose has been tolerated well, often defined as manageable side effects and stable injection technique.

The NHS provides patient-level information on tirzepatide, including common side effects at each stage, on its tirzepatide medicines page. The most commonly reported effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping. They are usually most noticeable after a dose increase, including the step to 7.5mg, and tend to settle within one to two weeks for most patients.

If side effects at 7.5mg are persistent or difficult, the clinical answer is a conversation with your prescriber, not a decision to halve the dose yourself or to pause treatment without guidance. The pen delivers 7.5mg as a unit; there is no built-in mechanism to take a fraction of it. For context on how the 5mg pen works, and how the click mechanism compares, the 5mg Mounjaro pen page covers that strength in the same detail.

Mounjaro holds a Black Triangle (▼) designation in the UK, indicating it is under additional MHRA monitoring. That status reflects how recently the medicine entered widespread use, not a signal about its safety relative to older medicines, it's the standard classification for newer products while post-market data accumulates. More on the treatment as a whole, including eligibility and what the licensed indications cover, is on the Mounjaro overview page.

Getting the dose right: where the pen ends and the prescriber begins

The KwikPen at 7.5mg does its job reliably when used correctly. The questions it can't answer are the clinical ones: whether 7.5mg is the right dose for you right now, whether a move to 10mg makes sense, and whether any symptoms you're experiencing warrant a change. Those questions go to a prescriber.

If you're considering private treatment or transferring from another provider, the treatment options page outlines how a clinical consultation with our prescribers works. There's also useful context on the Mounjaro golden dose page about the concept of an 'optimal' dose, it's worth reading before assuming that the highest dose is always the target. Cost context, for those comparing private providers, is covered on the Mounjaro cost guide.

The pen tells you one click delivers your 7.5mg dose. The rest is a clinical conversation. Speak to our prescribers if you have questions about where you are in your treatment.